ZBH Stock - Zimmer Biomet Holdings, Inc.
Unlock GoAI Insights for ZBH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.68B | $7.39B | $6.94B | $6.83B | $6.13B |
| Gross Profit | $5.49B | $5.31B | $4.92B | $4.87B | $4.30B |
| Gross Margin | 71.5% | 71.8% | 70.9% | 71.3% | 70.2% |
| Operating Income | $1.29B | $1.28B | $696.30M | $860.30M | $83.10M |
| Net Income | $903.80M | $1.02B | $231.40M | $401.60M | $-138,900,000 |
| Net Margin | 11.8% | 13.8% | 3.3% | 5.9% | -2.3% |
| EPS | $4.45 | $4.91 | $1.10 | $1.93 | $-0.67 |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 16th 2025 | Robert W. Baird | Downgrade | Neutral | $100 |
| November 6th 2025 | JP Morgan | Downgrade | Neutral | $100 |
| September 18th 2025 | Rothschild & Co Redburn | Initiation | Buy | $130 |
| July 15th 2025 | Roth Capital | Upgrade | Buy | $135 |
| December 17th 2024 | JP Morgan | Upgrade | Overweight | $128← $125 |
| September 10th 2024 | Wolfe Research | Initiation | Peer Perform | - |
| July 1st 2024 | Piper Sandler | Downgrade | Neutral | $115← $140 |
| May 30th 2024 | Goldman | Initiation | Neutral | $129 |
| May 21st 2024 | Argus | Upgrade | Buy | $150 |
| January 4th 2024 | Evercore ISI | Downgrade | In-line | $125← $135 |
| October 20th 2023 | ROTH MKM | Initiation | Neutral | $120 |
| August 28th 2023 | BTIG Research | Upgrade | Buy | $139 |
| May 3rd 2023 | BofA Securities | Upgrade | Neutral | - |
| April 11th 2023 | Evercore ISI | Upgrade | Outperform | $148← $135 |
| March 31st 2023 | Jefferies | Upgrade | Hold | $130← $115 |
Earnings History & Surprises
ZBHEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $2.38 | — | — | — |
Q4 2025 | Nov 5, 2025 | $1.87 | $1.90 | +1.6% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $1.98 | $2.07 | +4.5% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $1.77 | $1.81 | +2.3% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $2.30 | $2.31 | +0.4% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $1.74 | $1.74 | 0.0% | = MET |
Q3 2024 | Aug 7, 2024 | $1.99 | $2.01 | +1.0% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $1.87 | $1.94 | +3.7% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $2.15 | $2.20 | +2.3% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $1.59 | $1.65 | +3.8% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $1.82 | $1.82 | 0.0% | = MET |
Q2 2023 | May 2, 2023 | $1.66 | $1.89 | +13.9% | ✓ BEAT |
Q1 2023 | Feb 3, 2023 | $1.83 | $1.88 | +2.7% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $1.56 | $1.58 | +1.3% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $1.63 | $1.82 | +11.7% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $1.40 | $1.61 | +15.0% | ✓ BEAT |
Q1 2022 | Feb 7, 2022 | $1.96 | $1.95 | -0.5% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $1.75 | $1.81 | +3.4% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $1.84 | $1.90 | +3.3% | ✓ BEAT |
Latest News
Trump Administration Proposes Rule Banning Medicaid And CHIP From Paying For Gender Affirming Care
➖ NeutralZimmer Biomet Partners With OneStep To Offer Set Of Mobility Data For Surgeons
📈 PositiveBaird Downgrades Zimmer Biomet Holdings to Neutral, Lowers Price Target to $100
📉 NegativeCitigroup Maintains Neutral on Zimmer Biomet Holdings, Lowers Price Target to $94
➖ NeutralZimmer Biomet Receives FDA Clearance For An Enhanced Version Of Its ROSA Knee Robotic Technology
📈 PositiveCanaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Lowers Price Target to $93
📉 NegativeUBS Maintains Sell on Zimmer Biomet Holdings, Lowers Price Target to $88
📉 NegativeRBC Capital Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $101
➖ NeutralBarclays Maintains Underweight on Zimmer Biomet Holdings, Lowers Price Target to $104
📉 NegativeJP Morgan Downgrades Zimmer Biomet Holdings to Neutral, Lowers Price Target to $100
📉 NegativeBarclays Maintains Underweight on Zimmer Biomet Holdings, Lowers Price Target to $105
📉 NegativeBTIG Maintains Buy on Zimmer Biomet Holdings, Lowers Price Target to $112
➖ NeutralZimmer Biomet Holdings are trading lower after the company reported mixed Q3 financial results.
📉 NegativeZimmer Biomet Holdings Affirms FY2025 Adj EPS Guidance of $8.10-$8.30 vs $8.15 Est; Affirms FY2025 Sales Guidance of $8.190B-$8.270B vs $8.226B Est
📈 PositiveZimmer Biomet Holdings Q3 Adj. EPS $1.90 Beats $1.87 Estimate, Sales $2.001B Miss $2.005B Estimate
➖ NeutralFDA Grants Breakthrough Device Designation For Zimmer Biomet's First-To-World Iodine-Treated Total Hip Replacement System
📈 PositiveCanaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Maintains $101 Price Target
➖ NeutralBTIG Maintains Buy on Zimmer Biomet Holdings, Raises Price Target to $122
📈 PositiveEvercore ISI Group Maintains In-Line on Zimmer Biomet Holdings, Lowers Price Target to $104
➖ NeutralZimmer Biomet Secures PMDA Japan Approval For iTaperloc Complete And iG7 Hip Systems, Orthopedic Implants With Iodine Anti-Bacterial Technology
📈 PositiveFrequently Asked Questions about ZBH
What is ZBH's current stock price?
What is the analyst price target for ZBH?
What sector is Zimmer Biomet Holdings, Inc. in?
What is ZBH's market cap?
Does ZBH pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ZBH for comparison